FROM BANGLADESH TO THE WORLD

ADVANCING ACCESS
WITH QUALITY AND TRUST

IMPROVING LIVES THROUGH KNOWLEDGE AND QUALITY

GLOBAL STANDARDS ENSURING
CONSISTENT, HIGH-QUALITY
PHARMACEUTICAL EXCELLENCE

Who We Are

ACI HealthCare Limited is a quality-driven pharmaceutical company and a subsidiary of ACI PLC, established to serve global markets with integrity, compliance, and scientific discipline. Our foundation is built on internationally aligned quality frameworks, robust governance, and a culture of continuous improvement. We operate with a clear focus on regulated markets, ensuring that our systems, processes, and mindset consistently meet global expectations for reliability, transparency, and long-term partnership.

We develop, manufacture, and supply high-quality generic pharmaceutical products for regulated and emerging markets. Our capabilities span formulation development, technology transfer, and commercial-scale manufacturing, supported by compliant systems and data-driven operations. We also engage in contract manufacturing and strategic collaborations, enabling partners to access efficient, scalable, and quality-assured supply solutions across multiple geographies.

Production Capacity

1+ Billion Capsules
3+ Billion Tablets

Product Quantity

150+

Factory Site Area

37 Acre

SRA Compliant Facility

US FDA, EU GMP,
WHO

Multi-Region Export Capability

LATAM, ASEAN,
GCC, CIS, AFRICA

State-Of-The-Art Facility

ACI HealthCare Limited operates a modern pharmaceutical manufacturing facility designed to meet the stringent expectations of regulated international markets.

Know More

ACI HealthCare USA Inc.

ACI HealthCare USA Inc. serves as the strategic international interface of ACI HealthCare Limited, supporting market access, regulatory coordination, and business development activities in the United States.

Know More

Beyond The
Boundaries

ACI HealthCare Limited is committed to expanding beyond conventional market and operational limits to address evolving global healthcare needs. Our vision extends across geographies, technologies, and partnerships, enabling us to deliver accessible, quality medicines to diverse patient populations.

With a growing presence across the United States, Europe, Middle East & North Africa (MENA), Asia Pacific emerging markets, and Latin America (LATAM), we are continuously strengthening our global footprint. By combining scientific capability with strategic market insight, we explore new opportunities that enhance access, reliability, and long-term healthcare impact.

This forward-looking approach includes advancing into complex generics, future-ready delivery systems, and potential backward integration into APIs, while building strong collaborations across regulated and high-growth markets. Through innovation, scalability, and disciplined execution, we aim to move beyond boundaries creating sustainable value for healthcare systems, partners, and communities worldwide.

Manufacturing
Excellence

Quality
Management

Research &
Development

Sustainability

Key Highlights

Our defining strength is the delivery of global-standard pharmaceutical solutions, achieved through the seamless integration of stringent quality systems and an steadfast commitment to international regulatory excellence and integrity.

Azithromycin

ACI HealthCare Limited's Azithromycin represents a key milestone in our commitment to delivering globally trusted, high-quality anti-infective medicines. Developed and manufactured under internationally compliant GMP standards, this product reflects our strong capability in producing essential therapies with consistent quality and reliability.

Our Azithromycin has achieved WHO Prequalification (WHO PQ), a globally recognized endorsement of quality, safety, and efficacy enabling participation in international procurement programs and supporting access to medicines in high-need regions.

Backed by validated manufacturing processes, advanced analytical controls, and ICH-aligned stability programs, the product ensures consistent performance, controlled impurity profiles, and reliable therapeutic outcomes. It is designed to meet the expectations of both regulated and emerging markets, supporting broad global distribution.

More Products

Azithromycin Medicine Package by ACI HealthCare

Othera

ACI HealthCare Limited's Othera (Esomeprazole Magnesium Trihydrate USP) exemplifies our dedication to producing high-quality gastrointestinal therapies for global markets. Manufactured in our state-of-the-art facility under stringent GMP standards, Othera delivers consistent efficacy and pharmaceutical integrity.

Othera is formulated as a delayed-release tablet, ensuring optimal bioavailability and targeted therapeutic action. It is designed for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related disorders.

With robust stability data aligned to ICH guidelines and validated manufacturing processes, Othera meets the quality expectations of both regulated and emerging markets worldwide.

More Products